Nektar Therapeutics (NKTR) Shares Bought by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company increased its stake in shares of Nektar Therapeutics (NASDAQ:NKTR) by 3.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 114,357 shares of the biopharmaceutical company’s stock after purchasing an additional 3,683 shares during the quarter. The Manufacturers Life Insurance Company owned about 0.07% of Nektar Therapeutics worth $2,235,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Nektar Therapeutics by 14.1% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,603 shares of the biopharmaceutical company’s stock valued at $110,000 after purchasing an additional 692 shares during the last quarter. LS Investment Advisors LLC grew its stake in shares of Nektar Therapeutics by 8.8% during the second quarter. LS Investment Advisors LLC now owns 6,594 shares of the biopharmaceutical company’s stock valued at $129,000 after purchasing an additional 535 shares during the last quarter. Flinton Capital Management LLC lifted its holdings in Nektar Therapeutics by 75.7% in the second quarter. Flinton Capital Management LLC now owns 7,872 shares of the biopharmaceutical company’s stock valued at $154,000 after buying an additional 3,392 shares during the period. Riverhead Capital Management LLC lifted its holdings in Nektar Therapeutics by 78.7% in the second quarter. Riverhead Capital Management LLC now owns 8,754 shares of the biopharmaceutical company’s stock valued at $171,000 after buying an additional 3,854 shares during the period. Finally, World Asset Management Inc lifted its holdings in Nektar Therapeutics by 5.6% in the second quarter. World Asset Management Inc now owns 10,167 shares of the biopharmaceutical company’s stock valued at $199,000 after buying an additional 539 shares during the period. 95.13% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This article was first published by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another site, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this article can be viewed at https://www.com-unik.info/2017/11/05/nektar-therapeutics-nktr-shares-bought-by-the-manufacturers-life-insurance-company.html.

In other news, Director Roy A. Whitfield bought 35,000 shares of the company’s stock in a transaction dated Thursday, August 10th. The stock was bought at an average cost of $17.95 per share, for a total transaction of $628,250.00. Following the transaction, the director now owns 133,000 shares of the company’s stock, valued at $2,387,350. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Stephen K. Doberstein sold 1,701 shares of the business’s stock in a transaction that occurred on Wednesday, August 16th. The shares were sold at an average price of $19.32, for a total transaction of $32,863.32. Following the completion of the transaction, the senior vice president now owns 31,102 shares of the company’s stock, valued at $600,890.64. The disclosure for this sale can be found here. Insiders sold a total of 623,317 shares of company stock valued at $14,352,710 over the last 90 days. Corporate insiders own 6.10% of the company’s stock.

Shares of Nektar Therapeutics (NKTR) opened at $23.75 on Friday. The company has a debt-to-equity ratio of 72.60, a quick ratio of 3.82 and a current ratio of 3.97.

Nektar Therapeutics (NASDAQ:NKTR) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.04). The firm had revenue of $34.60 million during the quarter, compared to analyst estimates of $33.64 million. Nektar Therapeutics had a negative net margin of 157.14% and a negative return on equity of 1,223.34%. Nektar Therapeutics’s quarterly revenue was up 5.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.36) earnings per share. sell-side analysts anticipate that Nektar Therapeutics will post -0.95 earnings per share for the current fiscal year.

Several equities analysts recently weighed in on the stock. Mizuho assumed coverage on shares of Nektar Therapeutics in a report on Tuesday, September 26th. They issued a “buy” rating and a $30.00 price objective on the stock. ValuEngine upgraded shares of Nektar Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, September 1st. BidaskClub lowered shares of Nektar Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, August 23rd. Jefferies Group LLC reissued a “buy” rating and set a $23.00 price objective on shares of Nektar Therapeutics in a research report on Friday, August 18th. Finally, Evercore ISI started coverage on shares of Nektar Therapeutics in a research report on Thursday, August 17th. They issued an “in-line” rating and a $20.00 target price for the company. One research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have assigned a buy rating to the stock. Nektar Therapeutics has an average rating of “Buy” and an average target price of $26.80.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Want to see what other hedge funds are holding NKTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nektar Therapeutics (NASDAQ:NKTR).

Institutional Ownership by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

What are top analysts saying about Nektar Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Nektar Therapeutics and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit